SCHEMBL30774516

SCHEMBL30774516

CCOC(=O)Cc1c(N)cncc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
MAPK1 P28482 3/20 0.43
CHEK1 O14757 1/20 0.42
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 4/20 0.37
HSD17B10 Q99714 2/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15864578 1.00 SMN1; SMN2 (0.46) SMN1; SMN2MAPK1CHEK1CYP2C19CYP1A2
SCHEMBL15864377 0.77 ALDH1A1 (0.39) SMN1; SMN2MAPK1CYP2C19CYP1A2CYP3A4
SCHEMBL16694521 0.76 MAPT (0.47) SMN1; SMN2CYP2C19CYP1A2CYP3A4MEN1
SCHEMBL14991962 0.76 CYP2C19 (0.47) SMN1; SMN2CYP2C19CYP1A2CYP3A4MEN1
SCHEMBL15864269 0.74 SMN1; SMN2 (0.47) SMN1; SMN2MAPK1CYP2C19CYP1A2CYP3A4
SCHEMBL30774442 0.74 L3MBTL1 (0.37) SMN1; SMN2MAPK1CYP2C19CYP1A2CYP3A4
SCHEMBL6538425 0.73 CHEK1 (0.49) SMN1; SMN2MAPK1CHEK1KMT2AALDH1A1
SCHEMBL20517931 0.73 AOC3 (0.31)
SCHEMBL31394483 0.72 HSP90AB1 (0.40) SMN1; SMN2KMT2AALDH1A1HSD17B10GAA
SCHEMBL18276788 0.71 ALDH1A1 (0.50) SMN1; SMN2MAPK1CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 SMN1; SMN2 3395/4885MAPK1 1787/4885CHEK1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.